Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer stock (NYSE: PFE) lost about 5% in 2024 ... the last five years. Furthermore, the company’s initiatives to boost profitability should result in better earnings growth going forward.

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing ... While I wouldn't call it a growth stock, it could have market-beating potential at these prices.

However, before COVID-19, Pfizer enjoyed pretty healthy growth for many years. Looking ahead to 2025 and beyond, the stock seems to be priced at a very cheap level. Below are the earnings and ...

Pharmaceutical giant Pfizer (NYSE: PFE) is trading near its lowest price in over a decade. The company's revenue and profits ballooned during the pandemic on its COVID-19 vaccine and treatment.